Rapamycin: A rheostat for CD8+ T-cell-mediated tumor therapy

Rupesh K. Srivastava, Adam Utley, Protul A. Shrikant

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Vaccines that generate Ag-specific CD8+ T-cell responses of appropriate quality, magnitude and duration are highly desirable. The ability of mTOR to regulate CD8+ T-cell functional differentiation must be exploited for clinical benefit. In a recent paper, we report that varying the regimen of rapamycin administration regulates viral vaccine-induced CD8+ T-cell responses for tumor immunity. These observations validate the use of rapamycin in vaccination strategies and demonstrate the efficacy of memory CD8+ T-cell responses for tumor immunity.

Original languageEnglish (US)
Pages (from-to)1189-1190
Number of pages2
JournalOncoImmunology
Volume1
Issue number7
DOIs
StatePublished - Dec 1 2012

    Fingerprint

Keywords

  • Cancer
  • Memory CD8 T cells
  • Rapamycin
  • Vaccine
  • mTOR

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Srivastava, R. K., Utley, A., & Shrikant, P. A. (2012). Rapamycin: A rheostat for CD8+ T-cell-mediated tumor therapy. OncoImmunology, 1(7), 1189-1190. https://doi.org/10.4161/onci.20663